vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $8.1M, roughly 1.7× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -34.7%, a 43.4% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 5.2%). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs -26.3%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
AXIL vs FENC — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $13.8M |
| Net Profit | $704.9K | $-4.8M |
| Gross Margin | 68.1% | — |
| Operating Margin | 11.1% | -18.5% |
| Net Margin | 8.7% | -34.7% |
| Revenue YoY | 5.2% | 73.8% |
| Net Profit YoY | 11.2% | -141.1% |
| EPS (diluted) | $0.09 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $13.8M | ||
| Q3 25 | $6.9M | $12.5M | ||
| Q2 25 | $5.8M | $9.7M | ||
| Q1 25 | $6.9M | $8.8M | ||
| Q4 24 | $7.7M | $7.9M | ||
| Q3 24 | $5.9M | $7.0M | ||
| Q2 24 | $6.5M | $7.3M | ||
| Q1 24 | $6.5M | $25.4M |
| Q4 25 | $704.9K | $-4.8M | ||
| Q3 25 | $334.3K | $-638.0K | ||
| Q2 25 | $-245.6K | $-3.2M | ||
| Q1 25 | $576.7K | $-1.2M | ||
| Q4 24 | $633.7K | $-2.0M | ||
| Q3 24 | $-109.8K | $-5.7M | ||
| Q2 24 | $49.5K | $-5.6M | ||
| Q1 24 | $781.1K | $12.8M |
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | — | ||
| Q3 24 | 71.0% | — | ||
| Q2 24 | 71.5% | — | ||
| Q1 24 | 71.5% | — |
| Q4 25 | 11.1% | -18.5% | ||
| Q3 25 | 6.0% | -1.5% | ||
| Q2 25 | 0.8% | -28.3% | ||
| Q1 25 | 8.4% | -9.2% | ||
| Q4 24 | 8.7% | -11.8% | ||
| Q3 24 | -2.4% | -74.6% | ||
| Q2 24 | 2.6% | -69.4% | ||
| Q1 24 | -1.6% | 54.2% |
| Q4 25 | 8.7% | -34.7% | ||
| Q3 25 | 4.9% | -5.1% | ||
| Q2 25 | -4.3% | -32.7% | ||
| Q1 25 | 8.3% | -13.3% | ||
| Q4 24 | 8.2% | -25.0% | ||
| Q3 24 | -1.9% | -82.2% | ||
| Q2 24 | 0.8% | -76.5% | ||
| Q1 24 | 12.1% | 50.6% |
| Q4 25 | $0.09 | $-0.17 | ||
| Q3 25 | $0.04 | $-0.02 | ||
| Q2 25 | $-0.03 | $-0.11 | ||
| Q1 25 | $0.07 | $-0.04 | ||
| Q4 24 | $0.08 | $-0.02 | ||
| Q3 24 | $-0.02 | $-0.21 | ||
| Q2 24 | $0.11 | $-0.20 | ||
| Q1 24 | $0.04 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $36.8M |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $35.5M |
| Total Assets | $16.2M | $70.6M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $36.8M | ||
| Q3 25 | $4.1M | $21.9M | ||
| Q2 25 | $4.8M | $18.7M | ||
| Q1 25 | $4.7M | $22.7M | ||
| Q4 24 | $5.2M | $26.6M | ||
| Q3 24 | $4.1M | $40.3M | ||
| Q2 24 | $3.3M | $43.1M | ||
| Q1 24 | $4.9M | $51.2M |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | $19.4M | ||
| Q2 25 | $140.2K | $19.4M | ||
| Q1 25 | $141.0K | $19.4M | ||
| Q4 24 | $143.3K | $19.3M | ||
| Q3 24 | $144.3K | $32.1M | ||
| Q2 24 | $146.6K | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $11.1M | $35.5M | ||
| Q3 25 | $10.2M | $-4.5M | ||
| Q2 25 | $9.7M | $-7.5M | ||
| Q1 25 | $9.7M | $-5.9M | ||
| Q4 24 | $8.8M | $-5.9M | ||
| Q3 24 | $7.9M | $-5.2M | ||
| Q2 24 | $7.7M | $-1.4M | ||
| Q1 24 | $8.8M | $3.0M |
| Q4 25 | $16.2M | $70.6M | ||
| Q3 25 | $15.4M | $49.3M | ||
| Q2 25 | $12.9M | $44.9M | ||
| Q1 25 | $13.0M | $46.4M | ||
| Q4 24 | $13.7M | $44.9M | ||
| Q3 24 | $11.4M | $58.9M | ||
| Q2 24 | $11.0M | $63.2M | ||
| Q1 24 | $12.7M | $69.2M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-6.0M |
| Free Cash FlowOCF − Capex | $906.4K | — |
| FCF MarginFCF / Revenue | 11.1% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $-6.0M | ||
| Q3 25 | $-739.2K | $1.5M | ||
| Q2 25 | $194.4K | $-3.7M | ||
| Q1 25 | $-169.9K | $-4.3M | ||
| Q4 24 | $1.0M | $-1.5M | ||
| Q3 24 | $897.3K | $-2.2M | ||
| Q2 24 | $-336.6K | $-8.4M | ||
| Q1 24 | $-912.8K | $39.0M |
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-258.2K | — | ||
| Q4 24 | $941.1K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-394.9K | — | ||
| Q1 24 | $-922.1K | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.1% | — | ||
| Q1 24 | -14.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
FENC
Segment breakdown not available.
